If Boston Scientific is to come back, they will have to come back north of US$75 to keep this alive. They'll have to come back at least US$2 or more higher than they were.
It seems like Boston Scientific really wants this deal and will pull out all the stops to get it. It's a very rare asset. Cardiac rhythm management has $10 billion and only three companies.
Obviously, the Guidant board favors the certainty associated with J&J's offer. They've basically gotten the FTC to sign off with J&J. They just need shareholder approval.
The advantage to [metal implants] is that they're sterile. But the disadvantage is they don't remodel over time.
The cardiac rhythm management business is large -- $10 billion, highly profitable and it's an oligopoly.
The gold standard, if you will, is being able to have a label on the product that says it's sterile.
The overall number where there is actually a problem is still low, but more importantly, you've got, once again, a revelation that the problem is a little wider than first thought. What people had been hoping to see is some end to this.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.